The Ipsen Investment Case

A strong and expanding global footprint NORTH AMERICA 35% of total sales EUROPE5 31% of total sales REST OF WORLD 34% of total sales Compelling U.S. presence; strong commercial execution IPSEN Innovation for patient care 30+ countries with Ipsen presence Leveraging a significant European platform Attractive China infrastructure, emerging presence in new markets 100+ countries where Ipsen. medicines are marketed Based on FY 2021 Specialty Care sales; excludes Consumer Healthcare. EUROPE5: the U.K., France, Germany, Spain and Italy. 8

View entire presentation